H.C. Wainwright reiterates Buy on Connect Biopharma stock at $7

H.C. Wainwright reiterated a Buy rating on Connect Biopharma with a $7 price target, versus a $2.12 share price, implying meaningful upside. The company completed enrollment in its Phase 2 Seabreeze STAT Asthma study and expects topline data in early September 2026, while COPD data should follow soon after. The outlook is supported by analyst optimism and clinical progress, though the stock is still seen as overvalued and the company is burning cash.

Analysis

CNTB is behaving like a classic binary-event microcap where the equity is not yet pricing the platform, only the next readout. The key second-order effect is that positive Seabreeze data would not just validate one acute-asthma indication; it would reopen the market’s willingness to underwrite chronic respiratory and atopic-dermatitis optionality at materially lower implied probabilities, which is where most of the upside asymmetry lives.

The market is likely underestimating financing dilution as a near-term governor on upside. Even with cash on hand, a company burning through cash into a 2026 catalyst stack creates a funding overhang that can cap multiple expansion until data de-risks the story; if the stock rallies into the readout window, any equity raise would be accretive to runway but negative to per-share value.

The base-case setup is a volatility expansion trade rather than a clean directional long. A strong asthma readout could lift the stock sharply over days, but the more durable rerating would require evidence of onset speed and durability translating across COPD and chronic use cases over months; absent that, the move could fade once the market shifts from “proof of concept” to “commercial path and capital need.”

The contrarian miss is that the true comp may not be another small-cap biotech at all but larger immunology platforms with established commercial infrastructure. If management can credibly position rademikibart as a class-relevant asset with multiple shots on goal, the market could start valuing the program as a strategic acquisition candidate rather than a single-indication asset, especially if the data show differentiation in rapid onset and maintenance behavior.

Key Decisions for Investors

• Initiate a tactical long CNTB only into confirmed Seabreeze data, not ahead of it; treat it as a 1-3 week event-driven position with upside to the prior consensus range, but size for a potential 30-50% gap-down if efficacy misses.
• Buy CNTB calls or call spreads targeting the early-September 2026 asthma readout; prefer defined-risk structures because implied volatility should remain elevated and dilution risk makes common equity less attractive on a risk-adjusted basis.
• If already long, pair hedge with ABBV exposure only as a partial immunology beta offset, not a true hedge; the better protection is reducing gross exposure into the catalyst rather than assuming class-wide sympathy will hold.
• After a positive asthma readout, look to trade the follow-through into COPD enrollment completion and interim updates, but take profits on the first leg of the move; the second leg depends on whether data support chronic-disease expansion, which is a much higher bar.
• Avoid initiating a standalone short before the catalyst unless the stock re-rates far above the current analyst range; the upside squeeze risk into binary data is larger than the fundamental downside until trial timing passes.